Skip to content

Welcome to Discover Pharma! Today is : October 22, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

radiopharmaceuticals

  • Biotech & Pharma Business,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Telix to acquire ITM in $1.65BN radiopharmaceutical deal

    Telix has agreed to acquire ITM Isotope Technologies Munich in [...]

    September 21, 2026
  • Advanced Therapies,Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Oncoinvent publishes Radspherin dosimetry data in Journal of Nuclear Medicine

    Oncoinvent has published Phase 1 dosimetry data for Radspherin in [...]

    August 12, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    FDA issues Complete Response Letter for ITM-11 over manufacturing issues

    The FDA has issued a Complete Response Letter for ITM-11, [...]

    August 11, 2026
  • Digital & Data,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    AI model cuts radiopharmaceutical dose mapping to seconds in prostate cancer study

    A new AI model has generated patient-specific radiation dose-rate maps [...]

    August 5, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    Telix starts Phase 3 trial of radiopharmaceutical therapy for renal cancer

    Telix has dosed the first patient in a Phase 3 [...]

    July 22, 2026
  • Digital & Data,Drug Discovery & Development,Research & Development,Therapeutic Areas

    Nucs AI taps Segmed’s 150 million imaging studies to strengthen oncology AI

    Nucs AI has partnered with healthcare data specialist Segmed to [...]

    July 15, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    First patients dosed in Phase 1 trial of DLL3-targeted radiopharmaceutical for small cell lung cancer

    The first patients have been dosed with MP0712, a DLL3-targeted [...]

    July 3, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    FDA backs Telix Phase 3 ProstACT trial expansion into US

    Telix Pharmaceuticals has received FDA agreement on the protocol and [...]

    July 3, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Phase 3 data support PSMA-targeted radiopharmaceutical combination approach in advanced prostate cancer

    Phase 3 data presented at ASCO 2026 suggest a PSMA-targeted [...]

    June 6, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Manufacturing & Supply Chain,Therapeutic Areas

    Oncodesign expands ARRONAX deal to secure astatine-211 supply for radiotherapy research

    Oncodesign Services has expanded its collaboration with French research institute [...]

    May 5, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • E2 secures FDA clearance for pulmonary embolism thrombectomy system
    Categories: Clinical & Regulatory, Medical devices
  • Carterra and AstraZeneca target AI-driven drug discovery
    Categories: Biotech & Pharma Business, Digital & Data, Drug Discovery & Development, Research & Development
  • Biopharma dealmaking outlook improves despite investor caution
    Categories: Biotech & Pharma Business, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top